Management of Enterocutaneous Fistulas Worldwide: Challenges, Practices, and Outcomes

Öz

Enterocutaneous fistulas (ECFs) are among the most devastating complications in surgical practice. Management requires a multidisciplinary approach focused on sepsis control, nutritional optimization, fistula closure, and restoration of quality of life. A comprehensive review of PubMed and Google Scholar was conducted for the period from 2000 to 2025. Given the paucity of recent literature from low- and middle-income countries (LMICs), data from the past 25 years were included to capture broader insights into the topic. The Salford unit in the United Kingdom introduced the SNAP strategy (Sepsis, Nutrition, Anatomy, and Plan), which emphasizes infection control, nutritional support, anatomical definition, and surgical planning. While this structured approach has improved outcomes in high-income countries (HICs), its translation to LMICs remains challenging. Limited access to broad-spectrum antibiotics, advanced imaging, and modern wound care techniques hampers early management. Nutrition, which is central to fistula therapy, is optimized in HICs through tailored enteral and parenteral regimens. In contrast, LMICs often depend on modified oral or nasogastric feeding, which, although less effective, can provide reasonable outcomes when delivered consistently. Definitive management includes effluent control, skin protection, and surgical intervention. Advanced modalities such as negative pressure wound therapy (NPWT), octreotide, parenteral nutrition, and abdominal wall reconstruction with biological meshes are widely available in HICs. In LMICs, however, clinicians frequently rely on improvised NPWT systems, have limited access to pharmacological adjuncts and parenteral nutrition, and often resort to staged operations with fewer reconstructive options. This review highlights persistent management gaps in LMICs and emphasizes the urgent need for more robust data to better define challenges, guide policy, and adapt treatment strategies to resource-limited settings.

Anahtar Kelimeler

• Developing countries
• enterocutaneous fistula
• intestinal fistula
• negative-pressure wound therapy
• nutrition therapy
• sepsis

Dünya Çapında Enterokütanöz Fistül Yönetimi: Zorluklar, Uygulamalar ve Sonuçlar

Öz

Enterokütanöz fistüller (EKF), cerrahi pratiğin en yıkıcı komplikasyonları arasında yer almaktadır. Yönetim; sepsis kontrolü, beslenmenin optimizasyonu, fistülün kapatılması ve yaşam kalitesinin yeniden sağlanmasına odaklanan multidisipliner bir yaklaşım gerektirir. 2000–2025 dönemini kapsayan kapsamlı bir PubMed ve Google Scholar taraması yapılmıştır. Düşük ve orta gelirli ülkelerden (LMIC) güncel literatürün sınırlı olması göz önünde bulundurularak, konuya daha geniş bir bakış açısı kazandırmak amacıyla son 25 yılın verileri dahil edilmiştir. Birleşik Krallık’taki Salford ünitesi, enfeksiyon kontrolü, beslenme desteği, anatomik tanımlama ve cerrahi planlamayı vurgulayan SNAP stratejisini (Sepsis, Nutrition, Anatomy, Plan) geliştirmiştir. Bu yapılandırılmış yaklaşım yüksek gelirli ülkelerde (HIC) sonuçları iyileştirmiş olsa da, LMIC’lere uyarlanması çeşitli güçlükler taşımaktadır. Geniş spektrumlu antibiyotiklere, ileri görüntüleme yöntemlerine ve modern yara bakımına sınırlı erişim erken dönemde yönetimi zorlaştırmaktadır. Fistül tedavisinin merkezinde yer alan beslenme, HIC’lerde özelleştirilmiş enteral ve parenteral rejimlerle optimize edilmektedir. Buna karşın LMIC’lerde sıklıkla modifiye oral veya nazogastrik beslenmeye başvurulmakta olup, bu yöntemler daha az etkili olsa da düzenli uygulandığında makul sonuçlar sağlayabilmektedir. Kesin tedavi; fistül akıntısının kontrolünü, cilt korunmasını ve cerrahi girişimi kapsamaktadır. Negatif basınçlı yara tedavisi (NPWT), oktreotid, parenteral beslenme ve biyolojik greftlerle abdominal duvar rekonstrüksiyonu gibi ileri modaliteler HIC’lerde yaygın olarak uygulanmaktadır. Ancak LMIC’lerde klinisyenler çoğunlukla doğaçlama NPWT sistemlerine başvurmakta, farmakolojik adjuvanlara ve parenteral beslenmeye erişimleri sınırlı kalmakta ve rekonstrüktif seçeneklerin daha kısıtlı olduğu aşamalı operasyonlara yönelmektedir. Bu derleme, LMIC’lerde süregelen yönetim boşluklarını vurgulamakta ve zorlukların daha iyi tanımlanabilmesi, politikaların yönlendirilmesi ve tedavi stratejilerinin kaynak kısıtlı ortamlara uyarlanabilmesi için daha güçlü verilere duyulan acil ihtiyacın altını çizmektedir.

Anahtar Kelimeler

• Beslenme tedavisi
• enterokütanöz fistül
• intestinal fistül
• negatif basınçlı yara tedavisi
• sepsis

Kaynakça

1. 1. Ahmed M. Gastrointestinal fistulas: what gastroenterologists need to know in 2025. Can J Gastroenterol Hepatol. 2025;2025:6210421.
2. 2. Dionigi G, Dionigi R, Rovera F, et al. Treatment of high output enterocutaneous fistulae associated with large abdominal wall defects: single center experience. Int J Surg. 2008;6(1):51-56.
3. 3. Martínez-Ordaz JL, Luque-de-León E, Suárez-Moreno RM, Blanco-Benavides R. Fístulas enterocutáneas postoperatorias. Gac Med Mex. 2003;139(2):144-151.
4. 4. Candela G, Di Libero L, Varriale S, et al. Diagnostic and therapeutic guidelines for enterocutaneous fistulas: personal experience and literature review. Minerva Chir. 2007;62(4):293-303.
5. 5. Draganov K, Dimitrova V, Ionkov A, et al. Acquired enterocutaneous fistulas: diagnostic and therapeutic approach. Khirurgiia (Sofiia). 2005;(2):42-46.
6. 6. Dodiyi-Manuel A, Igwe PO. Enterocutaneous fistula in University of Port Harcourt Teaching Hospital. Niger J Med. 2013;22(2):93-96.
7. 7. Haack CI, Galloway JR, Srinivasan J. Enterocutaneous fistulas: a look at causes and management. Curr Surg Rep. 2014;2:71.
8. 8. Williams LJ, Zolfaghari S, Boushey RP. Complications of enterocutaneous fistulas and their management. Clin Colon Rectal Surg. 2010;23(3):209-220.

9. 9. Pepe G, Chiarello MM, Bianchi V, et al. Entero-cutaneous and entero-atmospheric fistulas: insights into management using negative pressure wound therapy. J Clin Med. 2024;13(5):1279.
10. 10. Njeze GE, Achebe UJ. Enterocutaneous fistula: a review of 82 cases. Niger J Clin Pract. 2013;16(2):174-177.
11. 11. Lloyd DAJ, Gabe SM, Windsor ACJ. Nutrition and management of enterocutaneous fistula. Br J Surg. 2006;93(9):1045-1055.
12. 12. Bawa D, Sule AZ, Grimah VA, et al. Experience with enterocutaneous fistula management in a district hospital in Nigeria. East Cent Afr J Surg. 2016;21(2):17-26.
13. 13. Kumar P, Maroju NK, Kate V. Enterocutaneous fistulae: etiology, treatment, and outcome—study from South India. Saudi J Gastroenterol. 2011;17(6):391-395.
14. 14. Badrasawi MMH, Shahar S, Sagap I. Nutritional management of enterocutaneous fistula: retrospective study at a Malaysian university medical center. J Multidiscip Healthc. 2014;7:365-370.
15. 15. Singh O, Gupta S, Moses S, Jain DK. Spontaneous tubercular enterocutaneous fistula developing in the scar of a surgery done 14 years earlier. Saudi J Gastroenterol. 2009;15(4):261-265.
16. 16. Shah M, Wani MA. Spontaneous tubercular enterocutaneous fistula. Saudi J Med Med Sci. 2017;5(3):275-277.
17. 17. Tan J, Porter D, Guo J, Pan L, Yang G, Zhang Z. Colonic tuberculosis with thoracolumbar enterocutaneous fecal fistulae: case report. J Med Cases. 2020;11(5):111-114.
18. 18. Pironi L, Arends J, Baxter JP, et al. ESPEN endorsed recommendations: definition and classification of intestinal failure in adults. Clin Nutr. 2015;34(2):171-180.
19. 19. Ajao OG, Shehri MY. Enterocutaneous fistula. Saudi J Gastroenterol. 2001;7(2):51-54.
20. 20. Dodiyi-Manuel A, Wichendu PN. Current concepts in management of enterocutaneous fistula. Int Surg J. 2018;5(6):1941-1946.
21. 21. Kaushal M, Carlson GL. Management of enterocutaneous fistulas. Clin Colon Rectal Surg. 2004;17(2):79-88.
22. 22. Noori IF. Postoperative enterocutaneous fistulas: management outcomes in 23 consecutive patients. Ann Med Surg (Lond). 2021;66:102413.
23. 23. Quinn M, Falconer S, McKee RF. Management of enterocutaneous fistula: outcomes in 286 patients. World J Surg. 2017;41(10):2502-2511.
24. 24. Blair K. Enterocutaneous fistulas in Uganda. Association for Academic Surgery. Accessed Aug 31, 2025. https://www.aasurg.org/enterocutaneous-fistulas-low-income-country/
25. 25. Chipu MG, Kearns I, Modula MJ. Exploration of critical care nurses' challenges in caring for enterocutaneous fistula as complication for open abdomen. Health Sci Rep. 2024;7(5):e2051.
26. 26. Gribovskaja-Rupp I, Melton GB. Enterocutaneous fistula: proven strategies and updates. Clin Colon Rectal Surg. 2016;29(2):130-137.
27. 27. Visschers RG, Olde Damink SW, Winkens B, Soeters PB, van Gemert WG. Treatment strategies in 135 consecutive patients with enterocutaneous fistulas. World J Surg. 2008;32(3):445-453.
28. 28. Sartelli M, Catena F, Coccolini F, Pinna AD. Antimicrobial management of intra-abdominal infections: literature's guidelines. World J Gastroenterol. 2012;18(9):865-881.
29. 29. Hollender LF, Meyer C, Avet D, Zeyer B. Postoperative fistulas of the small intestine: therapeutic principles. World J Surg. 1983;7(4):474-480.
30. 30. Safdar N, Saleem S, Salman M, et al. Economic burden of antimicrobial resistance on patients in Pakistan. Front Public Health. 2025;13:1481212.
31. 31. Saleem Z, Saeed H, Akbar Z, et al. WHO key access antibiotics price, availability and affordability in private sector pharmacies in Pakistan. Cost Eff Resour Alloc. 2021;19(1):10.
32. 32. Ukweh ON, Alswang JM, Iya-Benson JN, et al. Comparative analysis of percutaneous drainage versus operative drainage of intra-abdominal abscesses. Ann Glob Health. 2023;89(1):35.
33. 33. Hanifa R, Andayani DE. Route delivery of nutrition in patients with enterocutaneous fistula. Med J Malaysia. 2023;78(4).
34. 34. Dumas RP, Moore SA, Sims CA. Enterocutaneous fistula: evidence-based management. Clin Surg. 2017;2:1435.
35. 35. Tang QQ, Hong ZW, Ren HJ, et al. Nutritional management of patients with enterocutaneous fistulas: practice and progression. Front Nutr. 2020;7:564379.
36. 36. LLLNutrition. LLLNutrition website. Accessed Feb 17, 2026. https://www.lllnutrition.com
37. 37. Brown B, Roehl K, Betz M. Enteral nutrition formula selection: current evidence and implications for practice. Nutr Clin Pract. 2015;30(1):72-85.
38. 38. Klek S, Forbes A, Gabe S, et al. Management of acute intestinal failure: position paper from ESPEN. Clin Nutr. 2016;35(6):1209-1218.
39. 39. Udo IA, Umoh MS. Enterocutaneous fistula: a review of literature. Ibom Med J. 2008;3(1):13-17.
40. 40. Lee JK, Stein SL. Radiographic and endoscopic diagnosis and treatment of enterocutaneous fistulas. Clin Colon Rectal Surg. 2010;23(3):149-160.
41. 41. Nkengasong JN, Yao K, Onyebujoh P. Laboratory medicine in low-income and middle-income countries: progress and challenges. Lancet. 2018;391(10133):1873-1875.
42. 42. Shah DR, Leslie A, Destigter K, et al. Medical imaging: the missing element of national health plans. J Glob Radiol. 2021;7(2):11.
43. 43. Nyamuryekunge MK, Yango B, Mwanga A, Ali A. Improvised vacuum-assisted closure dressing for enterocutaneous fistula: case report. Int J Surg Case Rep. 2020;77:610-613.
44. 44. Lattuada D, Casnici C, Crotta K, et al. Inhibitory effect of pasireotide and octreotide on lymphocyte activation. J Neuroimmunol. 2007;182(1-2):153-159.
45. 45. Cooper A, Braatvedt GD, Qamar MI, et al. Fasting and post-prandial splanchnic blood flow reduced by somatostatin analogue (octreotide). Clin Sci. 1991;81:169-175.
46. 46. Fischer J. The importance of reconstruction of the abdominal wall after gastrointestinal fistula closure. Am J Surg. 2009;197:131-132.
47. 47. Carbonell AM, Matthews BD, Dréau D, et al. Susceptibility of prosthetic biomaterials to infection. Surg Endosc. 2005;19(3):430-435.
48. 48. Masiaga NM, Mwashambwa MY. Factors associated with management outcomes of enterocutaneous fistula patients. Int J Surg Res Pract. 2023;10:160.
49. 49. Nwabuoku SE, Kabara SB, Okafor FI, et al. Presentation and management outcomes of enterocutaneous fistula in a resource-poor setting. PHMJ. 2025;18(1):35-46.
50. 50. Okoli C, Oparaocha D, Onyemkpa C. Enterocutaneous fistula: aetiology and management outcome in a tertiary center in Nigeria. Afrimedic. 2013;4:17-21.